Fingerprint
Dive into the research topics of 'Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC)'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC)
From The Alliance for Clinical Trials in Oncology Genitourinary Committee
Research output: Contribution to journal › Article › peer-review
8
Scopus
citations